

# Nabil F Saba

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9561587/nabil-f-saba-publications-by-year.pdf>

**Version:** 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200  
papers

8,375  
citations

39  
h-index

87  
g-index

210  
ext. papers

10,872  
ext. citations

8.6  
avg, IF

5.77  
L-index

#	Paper	IF	Citations
200	ATAD3A mediates activation of RAS-independent mitochondrial ERK1/2 signaling, favoring head and neck cancer development.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 43	12.8	2
199	Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management - A Systematic Review.. <i>Cancer Management and Research</i> , <b>2022</b> , 14, 339-366	3.6	0
198	Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas.. <i>Oncologist</i> , <b>2022</b> , 27, 48-56	5.7	1
197	TP53 mutations in head and neck cancer.. <i>Molecular Carcinogenesis</i> , <b>2022</b> ,	5	2
196	Cervical Lymph Node Metastases from Central Nervous System Tumors: A Systematic Review.. <i>Cancer Management and Research</i> , <b>2022</b> , 14, 1099-1111	3.6	0
195	Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab.. <i>Oral Oncology</i> , <b>2022</b> , 127, 105787	4.4	1
194	Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. <i>Cancers</i> , <b>2022</b> , 14, 2355	6.6	1
193	A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. <i>Cancers</i> , <b>2022</b> , 14, 2639	6.6	1
192	0577 Sleep Quality and Its Association with Inflammation Over Time in Patients Undergoing Radiation Therapy for Head and Neck Cancer. <i>Sleep</i> , <b>2022</b> , 45, A254-A254	1.1	
191	Head and neck cancer: high-end technology is no guarantee of high-quality care [AuthorsPreply]. <i>Lancet, The</i> , <b>2022</b> , 399, 2102	4.0	
190	Incidence of Cancer Treatment Induced Arrhythmia Associated with Immune Checkpoint Inhibitors.. <i>Journal of Atrial Fibrillation</i> , <b>2021</b> , 13, 2461	0.8	1
189	The Hidden Link of Exosomes to Head and Neck Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
188	The omission of intentional primary site radiation following transoral robotic surgery in 59 patients: No local-regional failures. <i>Head and Neck</i> , <b>2021</b> , 44, 382	4.2	0
187	De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?. <i>Oral Oncology</i> , <b>2021</b> , 123, 105620	4.4	1
186	Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2101752	2.2	20
185	Defining HPV-specific B cell responses in patients with head and neck cancer. <i>Nature</i> , <b>2021</b> , 597, 274-278	50.4	48
184	Socioeconomic Factors Influence the Impact of Tumor HPV Status on Outcome of Patients With Oropharyngeal Squamous Cell Carcinoma. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e313-e322	2.3	2

183	Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	8
182	Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study. <i>Cancer</i> , <b>2021</b> , 127, 3361-3371	6.4	3
181	Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 6010-6010	2.2	9
180	The Proteomic Landscape of Growth Factor Signaling Networks Associated with Mutations in Head and Neck Cancers. <i>Cancer Research</i> , <b>2021</b> , 81, 4402-4416	10.1	3
179	TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS. <i>Oral Oncology</i> , <b>2021</b> , 117, 105294	4.4	0
178	Tipifarnib in Head and Neck Squamous Cell Carcinoma With Mutations. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1856-1864	2.2	31
177	Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
176	Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population. <i>Laryngoscope</i> , <b>2021</b> , 131, E921-E928	3.6	5
175	The role of the gut microbiome in cancer-related fatigue: pilot study on epigenetic mechanisms. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 3173-3182	3.9	12
174	Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma. <i>PLoS ONE</i> , <b>2021</b> , 16, e0247498	3.7	3
173	A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 109-122	7.5	3
172	Plasma Metabolic Phenotypes of HPV-Associated versus Smoking-Associated Head and Neck Cancer and Patient Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 1858-1866	4	
171	Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1. <i>Nature Communications</i> , <b>2021</b> , 12, 4960	17.4	7
170	Functional HPV-specific PD-1 stem-like CD8 T cells in head and neck cancer. <i>Nature</i> , <b>2021</b> , 597, 279-284	50.4	28
169	Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 111, 157-167	4	2
168	Head and neck cancer. <i>Lancet, The</i> , <b>2021</b> ,	40	36
167	Cancer of the Paranasal Sinuses. <i>Hematology/Oncology Clinics of North America</i> , <b>2021</b> , 35, 949-962	3.1	2
166	Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 393	12.8	3

165	Posttreatment Imaging in Patients with Head and Neck Cancer without Clinical Evidence of Recurrence: Should Surveillance Imaging Extend Beyond 6 Months?. <i>American Journal of Neuroradiology</i> , <b>2020</b> , 41, 1238-1244	4.4	3
164	Perioperative Antibiotics in Clean-Contaminated Head and Neck Surgery: A Systematic Review and Meta-Analysis. <i>Advances in Therapy</i> , <b>2020</b> , 37, 1360-1380	4.1	16
163	Narrowband Imaging for p16+ Unknown Primary Squamous Cell Carcinoma Prior to Transoral Robotic Surgery. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2020</b> , 163, 1198-1201	5.5	4
162	Demographic and Socioeconomic Factors Associated With Metastases at Presentation in HPV-Related Squamous Cell Carcinoma of the Head and Neck: An NCDB Analysis. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, e476-e487	2.3	1
161	Outcomes and Predictive Value of Post-adjuvant Therapy PET/CT for Locally Advanced Oral Squamous Cell Carcinoma. <i>Laryngoscope</i> , <b>2020</b> , 130, E850-E857	3.6	0
160	Current management of stage IV nasopharyngeal carcinoma without distant metastasis. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 85, 101995	14.4	10
159	Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment. <i>Current Treatment Options in Oncology</i> , <b>2020</b> , 21, 4	5.4	5
158	Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer. <i>Vaccines</i> , <b>2020</b> , 8,	5.3	6
157	Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC). <i>PLoS ONE</i> , <b>2020</b> , 15, e0238497	3.7	2
156	Exhaled breath analysis in the diagnosis of head and neck cancer. <i>Head and Neck</i> , <b>2020</b> , 42, 787-793	4.2	2
155	Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups. <i>Head and Neck</i> , <b>2020</b> , 42, 678-687	4.2	1
154	A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. <i>Oral Oncology</i> , <b>2020</b> , 110, 104797	11.4	13
153	Electronic Cigarettes and Head and Neck Cancer Risk-Current State of Art. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
152	Association Among Glucocorticoid Receptor Sensitivity, Fatigue, and Inflammation in Patients With Head and Neck Cancer. <i>Psychosomatic Medicine</i> , <b>2020</b> , 82, 508-516	3.7	4
151	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5860-5868	12.9	4
150	An update on the immune landscape in lung and head and neck cancers. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2020</b> , 70, 505-517	220.7	33
149	Gut Microbiome Associated with the Psychoneurological Symptom Cluster in Patients with Head and Neck Cancers. <i>Cancers</i> , <b>2020</b> , 12,	6.6	16
148	A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 999-1007	6.1	5

147	RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. <i>Frontiers in Genetics</i> , <b>2020</b> , 11, 598118	4.5	8
146	Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC) <b>2020</b> , 15, e0238497		
145	Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC) <b>2020</b> , 15, e0238497		
144	Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC) <b>2020</b> , 15, e0238497		
143	Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC) <b>2020</b> , 15, e0238497		
142	Small cell and large cell neuroendocrine carcinoma of the larynx: A comparative analysis. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 78, 42-51	14.4	10
141	Management of locally recurrent nasopharyngeal carcinoma. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 79, 101890	14.4	78
140	Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 484-493.e6	4.9	11
139	Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity-scored analysis of the National Cancer Data Base. <i>Cancer</i> , <b>2019</b> , 125, 2782-2793	6.4	19
138	Prognostic value of radiographically defined extranodal extension in human papillomavirus-associated locally advanced oropharyngeal carcinoma. <i>Head and Neck</i> , <b>2019</b> , 41, 3056-3063	4.2	11
137	Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 137, 84-91	7	24
136	Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. <i>Head and Neck</i> , <b>2019</b> , 41, 1490-1498	4.2	14
135	Prognosis of subglottic carcinoma: Is it really worse?. <i>Head and Neck</i> , <b>2019</b> , 41, 511-521	4.2	15
134	Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis. <i>Oncology</i> , <b>2019</b> , 97, 49-58	3.6	6
133	Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1295-1305	21.7	55
132	Nivolumab versus investigator choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. <i>Oral Oncology</i> , <b>2019</b> , 96, 7-14	4.4	23
131	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5221-5230	12.9	74
130	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , <b>2019</b> , 125, 3208-3218	6.4	44

129	Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3266-3274	2.2	40
128	Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 2431-2445	15.9	16
127	Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4110-4123	15.9	11
126	CDX3379-04: Phase II evaluation of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 6025-6025	2.3	1
125	Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 1909-1915	6.1	13
124	Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) Data. <i>Oncologist</i> , <b>2019</b> , 24, 1562-1589	5.7	11
123	Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas. <i>Laryngoscope</i> , <b>2019</b> , 129, 377-386	3.6	5
122	Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , <b>2019</b> , 13, 304-312	3.3	6
121	Prognostic implications of peritumoral vasculature in head and neck cancer. <i>Cancer Medicine</i> , <b>2019</b> , 8, 147-154	4.8	11
120	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, 195-203	13.4	141
119	Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx. <i>Cancer</i> , <b>2019</b> , 125, 704-711	6.4	11
118	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , <b>2018</b> , 81, 45-51	4.4	372
117	Head and Neck Cancer: A Review of the Impact of Treatment Delay on Outcome. <i>Advances in Therapy</i> , <b>2018</b> , 35, 153-160	4.1	38
116	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 710-716	6.1	20
115	A Review of Photodynamic Therapy for Neoplasms of the Head and Neck. <i>Advances in Therapy</i> , <b>2018</b> , 35, 324-340	4.1	53
114	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1583-1588	13.4	52
113	Time to Rethink Our Strategy With a Preoperative Intensification Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 762	4	
112	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. <i>Cancer Cell</i> , <b>2018</b> , 34, 315-330.e7	24.3	43

111	Associations among human papillomavirus, inflammation, and fatigue in patients with head and neck cancer. <i>Cancer</i> , <b>2018</b> , 124, 3163-3170	6.4	18
110	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , <b>2018</b> , 23, 1079-1082	5.7	44
109	Racial disparities in surgical management and survival in hispanic patients with potentially resectable esophageal cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4027-4027	2.2	1
108	Survival outcomes by HPV status in non-oro-pharyngeal head and neck cancers: A propensity score matched analysis of population level data.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6005-6005	2.2	1
107	Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6008-6008	2.2	11
106	ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6052-6052	2.2	1
105	A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus-associated head and neck squamous cell cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS6093-TPS6093	2.2	3
104	Deformable Registration of Histological Cancer Margins to Gross Hyperspectral Images using Demons. <i>Proceedings of SPIE</i> , <b>2018</b> , 10581,	1.7	6
103	Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 858-869	12.9	16
102	Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?. <i>Cancer</i> , <b>2018</b> , 124, 4163-4164	6.4	3
101	Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer. <i>Brain, Behavior, and Immunity</i> , <b>2018</b> , 74, 291-295	16.6	11
100	Systemic therapy in non-conventional cancers of the larynx. <i>Oral Oncology</i> , <b>2018</b> , 82, 61-68	4.4	12
99	Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer. <i>Orl</i> , <b>2018</b> , 80, 85-95	2	21
98	HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 677-686	12.9	46
97	Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials. <i>Auris Nasus Larynx</i> , <b>2017</b> , 44, 18-25	2.2	20
96	Association of Lymphovascular Space Invasion With Locoregional Failure and Survival in Patients With Node-Negative Oral Tongue Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2017</b> , 143, 382-388	3.9	21
95	Nasal juvenile angiofibroma: Current perspectives with emphasis on management. <i>Head and Neck</i> , <b>2017</b> , 39, 1033-1045	4.2	51
94	Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 115, 50-58	7	26

93	Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. <i>Cancer</i> , <b>2017</b> , 123, 3476-3485	6.4	27
92	An update on larynx cancer. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2017</b> , 67, 31-50	220.7	274
91	How phenotype guides management of non-conventional squamous cell carcinomas of the larynx?. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2017</b> , 274, 2709-2726	3.5	13
90	Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma. <i>American Journal of Neuroradiology</i> , <b>2017</b> , 38, 1193-1199	4.4	35
89	Otorhinolaryngological Toxicities of New Drugs in Oncology. <i>Advances in Therapy</i> , <b>2017</b> , 34, 866-894	4.1	1
88	ACR appropriateness criteria nasal cavity and paranasal sinus cancers. <i>Head and Neck</i> , <b>2017</b> , 39, 407-418	4.2	14
87	Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 286-292	4.9	34
86	Association of Cytoplasmic CXCR4 With Loss of Epithelial Marker and Activation of ERK1/2 and AKT Signaling Pathways in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, e203-e210	4.9	11
85	Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1120-1129	13.4	72
84	Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. <i>Head and Neck</i> , <b>2017</b> , 39, 2433-2443	4.2	4
83	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1542-1549	2.2	401
82	Refining the predictors of outcome in patients with resectable esophageal cancer. <i>Cancer</i> , <b>2017</b> , 123, 4097-4098	6.4	1
81	The Impact of Histologic Phenotype in the Treatment of Sinonasal Cancer. <i>Advances in Therapy</i> , <b>2017</b> , 34, 2181-2198	4.1	20
80	Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. <i>Head and Neck</i> , <b>2017</b> , 39, 2329-2349	4.2	15
79	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1104-1115	21.7	232
78	CT Accuracy of Extrinsic Tongue Muscle Invasion in Oral Cavity Cancer. <i>American Journal of Neuroradiology</i> , <b>2017</b> , 38, 364-370	4.4	8
77	Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 31	5.3	9
76	Resilience and biomarkers of health risk in Black smokers and nonsmokers. <i>Health Psychology</i> , <b>2017</b> , 36, 1047-1058	5	8



75	Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 1789-93	3.9	27
74	Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. <i>Cancer</i> , <b>2016</b> , 122, 50-60	6.4	30
73	A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , <b>2016</b> , 122, 3641-3649	6.4	22
72	The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2016</b> , 142, 898-905	3.9	11
71	Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. <i>Head and Neck</i> , <b>2016</b> , 38 Suppl 1, E2151-8	4.2	107
70	ACR Appropriateness Criteria( ) Aggressive Nonmelanomatous Skin Cancer of the Head and Neck. <i>Head and Neck</i> , <b>2016</b> , 38, 175-82	4.2	15
69	Is There a Role for PET/CT Parameters to Characterize Benign, Malignant, and Metastatic Parotid Tumors?. <i>American Journal of Roentgenology</i> , <b>2016</b> , 207, 635-40	5.4	12
68	ACR Appropriateness criteria for nasopharyngeal carcinoma. <i>Head and Neck</i> , <b>2016</b> , 38, 979-86	4.2	14
67	Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration?. <i>European Journal of Radiology</i> , <b>2016</b> , 85, 319-23	4.7	3
66	Fatigue is associated with inflammation in patients with head and neck cancer before and after intensity-modulated radiation therapy. <i>Brain, Behavior, and Immunity</i> , <b>2016</b> , 52, 145-152	16.6	42
65	Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2016</b> , 273, 2877-94	3.5	18
64	Development of Late Toxicities in Patients with Oral Tongue Cancer Treated with Surgical Resection and Adjuvant Radiation Therapy. <i>Frontiers in Oncology</i> , <b>2016</b> , 6, 272	5.3	2
63	Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?. <i>Annals of Translational Medicine</i> , <b>2016</b> , 4, 80	3.2	6
62	Biomarker quantification by multiplexed quantum dot technology for predicting lymph node metastasis and prognosis in head and neck cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 44676-44685	3.3	9
61	Complete Remission of Acute Myeloid Leukemia Following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer. <i>Case Reports in Hematology</i> , <b>2016</b> , 2016, 8581421	0.7	3
60	Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-Phenanthroline. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168450	3.7	3
59	Impact of neck failure on survival in older patients with differentiated thyroid cancer. <i>Head and Neck</i> , <b>2016</b> , 38, 919-24	4.2	
58	Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement. <i>Cancer</i> , <b>2016</b> , 122, 2150-7	6.4	25

57	A novel prediction model for human papillomavirus-associated oropharyngeal squamous cell carcinoma using p16 and subcellular $\beta$ -catenin expression. <i>Journal of Oral Pathology and Medicine</i> , <b>2016</b> , 45, 399-408	3.3	4
56	Clinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy. <i>Head and Neck</i> , <b>2016</b> , 38, 846-51	4.2	11
55	ACR Appropriateness Criteria(II) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. <i>Head and Neck</i> , <b>2016</b> , 38, 1299-309	4.2	8
54	The Challenges of Laryngeal Preservation-Is It the Systemic Agent or the Proper Sequence of Therapy?. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2016</b> , 142, 849-50	3.9	2
53	Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 111	8.5	58
52	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1856-1867	59.2	2647
51	Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation. <i>European Journal of Cancer</i> , <b>2016</b> , 65, 21-32	7.5	20
50	Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis. <i>Oral Oncology</i> , <b>2015</b> , 51, 586-92	4.4	39
49	A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2015</b> , 51, 376-82	4.4	41
48	Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. <i>Lung Cancer</i> , <b>2015</b> , 88, 80-4	5.9	16
47	A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1566-73	12.9	59
46	Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 479-85	8.9	43
45	Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?. <i>Clinical Nuclear Medicine</i> , <b>2015</b> , 40, e196-200	1.7	22
44	Targeting HER (ERBB) signaling in head and neck cancer: An essential update. <i>Molecular Aspects of Medicine</i> , <b>2015</b> , 45, 74-86	16.7	16
43	The role of systemic therapy in the management of sinonasal cancer: A critical review. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 836-43	14.4	79
42	Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention". <i>Oral Oncology</i> , <b>2015</b> , 51, 112-8	4.4	23
41	Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle. <i>Head and Neck Pathology</i> , <b>2015</b> , 9, 223-35	3.3	15
40	Human papillomavirus 16 oncoprotein regulates the translocation of $\beta$ -catenin via the activation of epidermal growth factor receptor. <i>Cancer</i> , <b>2015</b> , 121, 214-25	6.4	23

39	Lymph node ratio influence on risk of head and neck cancer locoregional recurrence after initial surgical resection: implications for adjuvant therapy. <i>Head and Neck</i> , <b>2015</b> , 37, 777-82	4.2	47
38	Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. <i>Cancer</i> , <b>2015</b> , 121, 3600-11	6.4	34
37	18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?. <i>European Journal of Radiology</i> , <b>2015</b> , 84, 1171-6	4.7	10
36	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1859-68	12.9	20
35	Targeted therapies in metastatic esophageal cancer: advances over the past decade. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 91, 186-96	7	28
34	Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. <i>Oral Oncology</i> , <b>2014</b> , 50, 888-94	4.4	15
33	Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 1826-36	6.1	51
32	ACR Appropriateness Criteria□ thyroid carcinoma. <i>Oral Oncology</i> , <b>2014</b> , 50, 577-86	4.4	8
31	Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , <b>2014</b> , 120, 3940-51	6.4	39
30	Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 1015-22	3.5	26
29	Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. <i>Cancer Prevention Research</i> , <b>2014</b> , 7, 283-91	3.2	52
28	Accuracy of computed tomography for predicting pathologic nodal extracapsular extension in patients with head-and-neck cancer undergoing initial surgical resection. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 122-9	4	77
27	Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck. <i>Head and Neck Pathology</i> , <b>2014</b> , 8, 66-72	3.3	26
26	Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , <b>2013</b> , 44, 143-51	1.6	57
25	Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009. <i>Cancer</i> , <b>2013</b> , 119, 2602-10	6.4	125
24	Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1244-56	12.9	50
23	Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. <i>Oncologist</i> , <b>2013</b> , 18, 600-10	5.7	27
22	Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 369-72	8.9	35

21	Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS6098-TPS6098	2.2	1
20	HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases?. <i>Head and Neck Pathology</i> , <b>2012</b> , 6, 336-44	3.3	48
19	Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. <i>Cancer</i> , <b>2012</b> , 118, 4444-51	6.4	194
18	Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors. <i>Chemotherapy Research and Practice</i> , <b>2012</b> , 2012, 291421	0	
17	Patterns of extralaryngeal spread of laryngeal cancer: thyroid cartilage penetration occurs in a minority of patients with extralaryngeal spread of laryngeal squamous cell cancers. <i>Cancer</i> , <b>2011</b> , 117, 5047-51	6.4	21
16	Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis. <i>Oncology</i> , <b>2011</b> , 81, 12-20	3.6	83
15	Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. <i>Cancer</i> , <b>2010</b> , 116, 3903-9	6.4	35
14	Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. <i>Cancer Prevention Research</i> , <b>2009</b> , 2, 823-9	3.2	35
13	Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis. <i>Head and Neck</i> , <b>2009</b> , 31, 1447-55	4.2	13
12	Percutaneous feeding tubes in patients with head and neck cancer: rethinking prophylactic placement for patients undergoing chemoradiation. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , <b>2009</b> , 30, 244-9	2.8	27
11	Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents. <i>Current Opinion in Oncology</i> , <b>2009</b> , 21, 232-7	4.2	9
10	Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation. <i>Cancer</i> , <b>2008</b> , 113, 97-107	6.4	59
9	Moving toward bioadjuvant approaches to head and neck cancer prevention. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, S132-5	4	4
8	Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. <i>Oncology</i> , <b>2006</b> , 20, 153-61; discussion 162, 166, 169 passim	1.8	13
7	Retinoids as chemoprevention for head and neck cancer: where do we go from here?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2005</b> , 55, 143-52	7	33
6	Chemoprevention in lung cancer. <i>Current Problems in Cancer</i> , <b>2004</b> , 28, 287-306	2.3	3
5	Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. <i>Blood</i> , <b>2003</b> , 102, 2678-83	2.2	435
4	Bone marrow transplantation for nonmalignant diseases. <i>Journal of Hematotherapy and Stem Cell Research</i> , <b>2002</b> , 11, 377-87		18

3	Overview of autologous stem cell transplantation. <i>Critical Reviews in Oncology/Hematology</i> , <b>2000</b> , 36, 27-48	7	19
2	Metastatic signet-ring cell adenocarcinoma to the urinary bladder. <i>Acta Oncologica</i> , <b>1997</b> , 36, 219-20	3.2	13
1	Designing and Conducting Phase III Studies		